JP2002523498A
(ja)
|
1998-08-29 |
2002-07-30 |
アストラゼネカ・アクチエボラーグ |
ピリミジン化合物
|
AU5438299A
(en)
|
1998-08-29 |
2000-03-21 |
Astrazeneca Ab |
Pyrimidine compounds
|
AU760020B2
(en)
*
|
1998-08-31 |
2003-05-08 |
Merck & Co., Inc. |
Novel angiogenesis inhibitors
|
GB9828511D0
(en)
|
1998-12-24 |
1999-02-17 |
Zeneca Ltd |
Chemical compounds
|
US6265403B1
(en)
*
|
1999-01-20 |
2001-07-24 |
Merck & Co., Inc. |
Angiogenesis inhibitors
|
PL205557B1
(pl)
|
1999-02-10 |
2010-05-31 |
Astrazeneca Ab |
Pochodne indolu
|
GB9905075D0
(en)
|
1999-03-06 |
1999-04-28 |
Zeneca Ltd |
Chemical compounds
|
US6245759B1
(en)
*
|
1999-03-11 |
2001-06-12 |
Merck & Co., Inc. |
Tyrosine kinase inhibitors
|
EP1188244B1
(fr)
*
|
1999-03-26 |
2004-11-10 |
Microsoft Corporation |
Codage adaptatif sans perte de donnees alphabetiques finies
|
GB9907658D0
(en)
|
1999-04-06 |
1999-05-26 |
Zeneca Ltd |
Chemical compounds
|
GB9919778D0
(en)
|
1999-08-21 |
1999-10-27 |
Zeneca Ltd |
Chemical compounds
|
UA74803C2
(uk)
|
1999-11-11 |
2006-02-15 |
Осі Фармасьютікалз, Інк. |
Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
|
GB0004890D0
(en)
|
2000-03-01 |
2000-04-19 |
Astrazeneca Uk Ltd |
Chemical compounds
|
GB0004886D0
(en)
|
2000-03-01 |
2000-04-19 |
Astrazeneca Uk Ltd |
Chemical compounds
|
GB0004888D0
(en)
|
2000-03-01 |
2000-04-19 |
Astrazeneca Uk Ltd |
Chemical compounds
|
GB0004887D0
(en)
|
2000-03-01 |
2000-04-19 |
Astrazeneca Uk Ltd |
Chemical compounds
|
GB0007371D0
(en)
|
2000-03-28 |
2000-05-17 |
Astrazeneca Uk Ltd |
Chemical compounds
|
US20020061897A1
(en)
|
2000-03-30 |
2002-05-23 |
Elliott Richard L. |
Neuropeptide Y antagonists
|
GB0016877D0
(en)
|
2000-07-11 |
2000-08-30 |
Astrazeneca Ab |
Chemical compounds
|
KR100834823B1
(ko)
|
2000-08-09 |
2008-06-09 |
아스트라제네카 아베 |
신놀린 화합물
|
WO2002012226A1
(fr)
|
2000-08-09 |
2002-02-14 |
Astrazeneca Ab |
Derives de la quinoline presentant une activite inhibant le facteur de croissance vegf
|
GB0021726D0
(en)
|
2000-09-05 |
2000-10-18 |
Astrazeneca Ab |
Chemical compounds
|
US7067520B2
(en)
|
2000-11-17 |
2006-06-27 |
Ishihara Sangyo Kaisha, Ltd. |
Preventive or therapeutic medicines for diabetes containing fused-heterocyclic compounds or their salts
|
SI2311825T1
(sl)
|
2000-12-21 |
2016-02-29 |
Novartis Ag |
Pirimidinamini kot angiogenetski modulatorji
|
PE20020801A1
(es)
|
2001-01-05 |
2002-09-06 |
Pfizer |
Anticuerpos contra el receptor del factor de crecimiento similar a insulina
|
GB0103926D0
(en)
|
2001-02-17 |
2001-04-04 |
Astrazeneca Ab |
Chemical compounds
|
GB0113041D0
(en)
|
2001-05-30 |
2001-07-18 |
Astrazeneca Ab |
Chemical compounds
|
AU2002345792A1
(en)
|
2001-06-21 |
2003-01-08 |
Pfizer Inc. |
Thienopyridine and thienopyrimidine anticancer agents
|
AR039067A1
(es)
|
2001-11-09 |
2005-02-09 |
Pfizer Prod Inc |
Anticuerpos para cd40
|
US7279473B2
(en)
|
2001-12-17 |
2007-10-09 |
Smithkline Beecham Corporation |
Pyrazolopyridazine derivatives
|
KR101093345B1
(ko)
|
2002-02-01 |
2011-12-14 |
아스트라제네카 아베 |
퀴나졸린 화합물
|
EP1483268A2
(fr)
|
2002-03-01 |
2004-12-08 |
Pfizer Inc. |
Derives indolyl-uree de thienopyridines utilises comme agents antiangiogeniques, et leurs methodes d'utilisation
|
GB0205688D0
(en)
|
2002-03-09 |
2002-04-24 |
Astrazeneca Ab |
Chemical compounds
|
GB0205690D0
(en)
|
2002-03-09 |
2002-04-24 |
Astrazeneca Ab |
Chemical compounds
|
GB0205693D0
(en)
|
2002-03-09 |
2002-04-24 |
Astrazeneca Ab |
Chemical compounds
|
JP2005524672A
(ja)
|
2002-03-09 |
2005-08-18 |
アストラゼネカ アクチボラグ |
Cdk阻害活性を有するイミダゾリル置換ピリミジン誘導体
|
ES2287476T3
(es)
|
2002-05-10 |
2007-12-16 |
Smithkline Beecham Corporation |
Pirazolopirimidinas sustituidas.
|
UA77303C2
(en)
|
2002-06-14 |
2006-11-15 |
Pfizer |
Derivatives of thienopyridines substituted by benzocondensed heteroarylamide useful as therapeutic agents, pharmaceutical compositions and methods for their use
|
RS20050430A
(en)
|
2002-12-19 |
2007-08-03 |
Pfizer Inc., |
2-(1h-indazol-6-ylamino)-benzamide compounds as protein kinases inhibitors useful for the treatment of ophtalmic diseases
|
BRPI0407827B8
(pt)
|
2003-02-26 |
2021-05-25 |
Sugen Inc |
compostos de aminoeteroarila como inibidores de proteína cinase e respectivos usos
|
KR20050115252A
(ko)
|
2003-02-28 |
2005-12-07 |
데이진 화-마 가부시키가이샤 |
피라졸로[1,5-a]피리미딘 유도체
|
EP1608652A1
(fr)
*
|
2003-03-31 |
2005-12-28 |
Vernalis (Cambridge) Limited |
Composes pyrazolopyrimidines et leur utilisation en medecine
|
GB0311276D0
(en)
|
2003-05-16 |
2003-06-18 |
Astrazeneca Ab |
Chemical compounds
|
GB0311274D0
(en)
|
2003-05-16 |
2003-06-18 |
Astrazeneca Ab |
Chemical compounds
|
GB0314262D0
(en)
|
2003-06-19 |
2003-07-23 |
Univ Nottingham Trent |
Novel compounds and methods of using the same
|
WO2005021554A1
(fr)
|
2003-08-29 |
2005-03-10 |
Pfizer Inc. |
Thienopyridine-phenylacetamides et leurs derives utiles comme nouveaux agents anti-angiogeniques
|
AR045563A1
(es)
|
2003-09-10 |
2005-11-02 |
Warner Lambert Co |
Anticuerpos dirigidos a m-csf
|
DE10356579A1
(de)
|
2003-12-04 |
2005-07-07 |
Merck Patent Gmbh |
Aminderivate
|
WO2005063756A1
(fr)
*
|
2003-12-22 |
2005-07-14 |
Sb Pharmco Puerto Rico Inc |
Antagonistes du recepteur de crf et procedes correspondants
|
OA13349A
(en)
|
2003-12-23 |
2007-04-13 |
Pfizer |
Novel quinoline derivatives.
|
GB0330002D0
(en)
|
2003-12-24 |
2004-01-28 |
Astrazeneca Ab |
Quinazoline derivatives
|
TW200528101A
(en)
|
2004-02-03 |
2005-09-01 |
Astrazeneca Ab |
Chemical compounds
|
PL1786785T3
(pl)
|
2004-08-26 |
2010-08-31 |
Pfizer |
Enancjomerycznie czyste związki aminoheteroarylowe jako kinazy białkowe
|
WO2006033795A2
(fr)
*
|
2004-09-17 |
2006-03-30 |
Wyeth |
Methode d'utilisation de pyrazolo [1,5-a] pyrimidines substituees
|
EP2444099A1
(fr)
|
2005-03-31 |
2012-04-25 |
Agensys, Inc. |
Anticorps et molécules correspondantes se liant aux protéines 161P2F10B
|
KR100990027B1
(ko)
|
2005-04-26 |
2010-10-26 |
화이자 인코포레이티드 |
P-카드헤린 항체
|
RS54393B1
(en)
|
2005-09-07 |
2016-04-28 |
Amgen Fremont Inc. |
HUMAN MONOCLONAL ANTIBODIES ON KINASE-1 SIMILAR TO ACTIVE RECEPTOR
|
ES2374450T3
(es)
|
2005-09-20 |
2012-02-16 |
OSI Pharmaceuticals, LLC |
Marcadores biológicos predictivos de respuesta anticancerígena para inhibidores de cinasa del receptor del factor de crecimiento 1 similar a insulina.
|
UY29826A1
(es)
|
2005-09-30 |
2007-04-30 |
Astrazeneca Ab |
Derivados de pirimidina, sales farmaceuticamente aceptables, esteres de los mismos hidrolisables in vivo, procesos de preparacion y aplicaciones
|
EP1931676B1
(fr)
|
2005-10-06 |
2011-11-16 |
Schering Corporation |
Pyrazolopyrimidines en tant qu'inhibiteurs de protéines kinases
|
JP4383525B2
(ja)
|
2006-05-09 |
2009-12-16 |
ファイザー・プロダクツ・インク |
シクロアルキルアミノ酸誘導体およびその医薬組成物
|
EP1900739A1
(fr)
*
|
2006-08-30 |
2008-03-19 |
Cellzome Ag |
Dérivés de diazolodiazine comme inhibiteurs de kinases
|
US20100093760A1
(en)
*
|
2006-09-12 |
2010-04-15 |
The General Hospital Corporation |
Methods for identifying compounds that modulate cell signaling and methods employing such compounds
|
MY146474A
(en)
*
|
2006-11-06 |
2012-08-15 |
Supergen Inc |
Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors
|
US8131527B1
(en)
|
2006-12-22 |
2012-03-06 |
Astex Therapeutics Ltd. |
FGFR pharmacophore compounds
|
CA2672213C
(fr)
|
2006-12-22 |
2016-02-16 |
Astex Therapeutics Limited |
Derives d'amine bicyclique en tant qu'inhibiteurs de tyrosine kinase
|
EP2178375B1
(fr)
|
2007-07-20 |
2014-09-24 |
Merck Sharp & Dohme Corp. |
Dérivés de la pyrazoloý1,5-a¨pyrimidine
|
EP2185574B1
(fr)
|
2007-09-07 |
2013-05-08 |
Agensys, Inc. |
Anticorps et molécules apparentées qui se lient aux protéines 24p4c12
|
GB0720041D0
(en)
|
2007-10-12 |
2007-11-21 |
Astex Therapeutics Ltd |
New Compounds
|
GB0720038D0
(en)
|
2007-10-12 |
2007-11-21 |
Astex Therapeutics Ltd |
New compounds
|
JP5643105B2
(ja)
*
|
2007-12-14 |
2014-12-17 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
新規イミダゾ[1,2−a]ピリジン及びイミダゾ[1,2−b]ピリダジン誘導体
|
NZ586662A
(en)
|
2007-12-19 |
2012-08-31 |
Vertex Pharma |
PYRAZOLO[1,5-a]PYRIMIDINES USEFUL AS JANUS KINASE 2 INHIBITORS
|
EP2265603B1
(fr)
|
2008-03-13 |
2014-05-07 |
The General Hospital Corporation |
Inhibiteurs de la voie de signalisation bmp
|
GB0810902D0
(en)
|
2008-06-13 |
2008-07-23 |
Astex Therapeutics Ltd |
New compounds
|
JP5836125B2
(ja)
|
2008-10-16 |
2015-12-24 |
ユニバーシティ オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション |
高分子量メラノーマ関連抗原に対する完全ヒト抗体およびその使用
|
EP2393814A1
(fr)
|
2009-02-09 |
2011-12-14 |
SuperGen, Inc. |
Inhibiteurs pyrrolopyrimidinyle de l'axi kinase
|
EP2400985A2
(fr)
|
2009-02-25 |
2012-01-04 |
OSI Pharmaceuticals, LLC |
Thérapie anti-cancer combinée
|
JP2012519170A
(ja)
|
2009-02-26 |
2012-08-23 |
オーエスアイ・ファーマシューティカルズ,エルエルシー |
生体内の腫瘍細胞のemtステータスをモニターするためのinsitu法
|
WO2010099138A2
(fr)
|
2009-02-27 |
2010-09-02 |
Osi Pharmaceuticals, Inc. |
Procédés pour l'identification d'agents qui inhibent les cellules tumorales de type mésenchymateuses ou leur formation
|
EP2401613A2
(fr)
|
2009-02-27 |
2012-01-04 |
OSI Pharmaceuticals, LLC |
Méthodes d'identification d'agents qui inhibent les cellules cancéreuses mésenchymateuses ou leur formation
|
TW201035088A
(en)
|
2009-02-27 |
2010-10-01 |
Supergen Inc |
Cyclopentathiophene/cyclohexathiophene DNA methyltransferase inhibitors
|
WO2010099363A1
(fr)
|
2009-02-27 |
2010-09-02 |
Osi Pharmaceuticals, Inc. |
Méthodes d'identification d'agents qui inhibent les cellules cancéreuses mésenchymateuses ou leur formation
|
GB0906470D0
(en)
|
2009-04-15 |
2009-05-20 |
Astex Therapeutics Ltd |
New compounds
|
GB0906472D0
(en)
|
2009-04-15 |
2009-05-20 |
Astex Therapeutics Ltd |
New compounds
|
CN102482715A
(zh)
|
2009-07-13 |
2012-05-30 |
霍夫曼-拉罗奇有限公司 |
用于癌症治疗的诊断方法和组合物
|
WO2011014726A1
(fr)
|
2009-07-31 |
2011-02-03 |
Osi Pharmaceuticals, Inc. |
Polythérapie par inhibiteur de mtor et inhibiteur de langiogenèse
|
JP2013503846A
(ja)
|
2009-09-01 |
2013-02-04 |
ファイザー・インク |
ベンズイミダゾール誘導体
|
KR20120105423A
(ko)
|
2009-09-11 |
2012-09-25 |
제넨테크, 인크. |
항암제에 반응할 증가된 가능성을 갖는 환자를 확인하는 방법
|
BR112012005670A2
(pt)
|
2009-09-17 |
2017-01-10 |
Hoffmann La Roche |
''método para a identificação de um paciente com câncer que pode se beneficiar com a terapia antiagiogênica, método para a predição da responsividade de um paciente com câncer à terapia antiangiogênica, uso de um anticorpo anto- vegf para melhorar o efeito do tratamento de um paciente sofrendo de câncer, método ou uso, kit útil para realizar o método, uso de uma proteína ou usom kit útil para realizar o método, uso de uma proteína ou oligonucleotídeo ou matriz de polinecleotídeo para determinar o nível de expressão de bfgf em um método e kit ou uso
|
WO2011073521A1
(fr)
|
2009-12-15 |
2011-06-23 |
Petri Salven |
Méthodes pour l'enrichissement de cellules progénitrices endothéliales adultes et leurs utilisations
|
MX343383B
(es)
|
2010-02-12 |
2016-11-03 |
Pfizer Inc * |
Sales y polimorfos de 8-fluoro-2-{4-[(metilamino)metil]fenil}-1,3, 4,5-tetrahidro-6h-acepino[5,4,3-cd]indol-6-ona.
|
WO2011109584A2
(fr)
|
2010-03-03 |
2011-09-09 |
OSI Pharmaceuticals, LLC |
Marqueurs biologiques prédictifs d'une réponse anticancéreuse aux inhibiteurs de kinase du récepteur du facteur de croissance insulinique 1
|
US20110275644A1
(en)
|
2010-03-03 |
2011-11-10 |
Buck Elizabeth A |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
|
US8815874B2
(en)
|
2010-03-05 |
2014-08-26 |
Kyowa Hakko Kirin Co., Ltd. |
Pyrazolopyrimidine derivative
|
WO2011153224A2
(fr)
|
2010-06-02 |
2011-12-08 |
Genentech, Inc. |
Procédés diagnostiques et compositions de traitement du cancer
|
EP2582727B8
(fr)
|
2010-06-16 |
2017-04-19 |
University of Pittsburgh- Of the Commonwealth System of Higher Education |
Anticorps dirigés contre l'endoplasmine et leur utilisation
|
BR112013001429A2
(pt)
|
2010-07-19 |
2016-05-31 |
Hoffmann La Roche |
método de identificação de pacientes com maior probabilidade de responder a terapia anticâncer
|
CA2804246A1
(fr)
|
2010-07-19 |
2012-01-26 |
F. Hoffmann-La Roche Ag |
Methode d'identification d'un patient presentant une probabilite accrue de repondre a un traitement anticancereux
|
SG187592A1
(en)
|
2010-07-23 |
2013-03-28 |
Univ Boston |
Anti-despr inhibitors as therapeutics for inhibition of pathological angiogenesis and tumor cell invasiveness and for molecular imaging and targeted delivery
|
WO2012042421A1
(fr)
|
2010-09-29 |
2012-04-05 |
Pfizer Inc. |
Procédé de traitement de la croissance cellulaire anormale
|
US9056865B2
(en)
|
2010-10-20 |
2015-06-16 |
Pfizer Inc. |
Pyridine-2-derivatives as smoothened receptor modulators
|
WO2012116040A1
(fr)
|
2011-02-22 |
2012-08-30 |
OSI Pharmaceuticals, LLC |
Marqueurs biologiques prédictifs d'une réponse anticancéreuse aux inhibiteurs de la kinase du récepteur du facteur de croissance 1 analogue à l'insuline dans le carcinome hépatocellulaire
|
US8748435B2
(en)
|
2011-04-01 |
2014-06-10 |
Novartis Ag |
Pyrazolo pyrimidine derivatives
|
US9150644B2
(en)
|
2011-04-12 |
2015-10-06 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Human monoclonal antibodies that bind insulin-like growth factor (IGF) I and II
|
US20140178368A1
(en)
|
2011-04-19 |
2014-06-26 |
Leslie Lynne SHARP |
Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer
|
WO2012149014A1
(fr)
|
2011-04-25 |
2012-11-01 |
OSI Pharmaceuticals, LLC |
Utilisation de signatures de gènes de tem dans la découverte de médicaments contre le cancer, diagnostics et traitement du cancer
|
JP2014517079A
(ja)
|
2011-06-22 |
2014-07-17 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
Atrキナーゼ阻害剤として有用な化合物
|
PL3409278T3
(pl)
|
2011-07-21 |
2021-02-22 |
Sumitomo Pharma Oncology, Inc. |
Heterocykliczne inhibitory kinazy białkowej
|
CN104023729A
(zh)
|
2011-09-02 |
2014-09-03 |
协和发酵麒麟株式会社 |
趋化因子受体活性调节剂
|
JP5914667B2
(ja)
|
2011-09-22 |
2016-05-11 |
ファイザー・インク |
ピロロピリミジンおよびプリン誘導体
|
ES2654160T3
(es)
|
2011-10-04 |
2018-02-12 |
Igem Therapeutics Limited |
Anticuerpos de IgE anti-HMW-MAA
|
RU2014114015A
(ru)
|
2011-11-08 |
2015-12-20 |
Пфайзер Инк. |
Способы лечения воспалительных расстройств с использованием антител против m-csf
|
WO2013152252A1
(fr)
|
2012-04-06 |
2013-10-10 |
OSI Pharmaceuticals, LLC |
Polythérapie antinéoplasique
|
ES2644758T3
(es)
|
2012-10-16 |
2017-11-30 |
Tolero Pharmaceuticals, Inc. |
Moduladores de PKM2 y métodos para su uso
|
SI3808749T1
(sl)
|
2012-12-07 |
2023-07-31 |
Vertex Pharmaceuticals Incorporated |
Pirazolo(1,5-A)pirimidini za uporabo kot zaviralci ATR kinaze pri zdravljenju rakavih bolezni
|
US9260426B2
(en)
|
2012-12-14 |
2016-02-16 |
Arrien Pharmaceuticals Llc |
Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors
|
ES2738493T3
(es)
|
2013-03-14 |
2020-01-23 |
Tolero Pharmaceuticals Inc |
Inhibidores de JAK2 y ALK2 y métodos para su uso
|
JP2016512815A
(ja)
|
2013-03-15 |
2016-05-09 |
バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated |
Atrキナーゼの阻害剤として有用な縮合ピラゾロピリミジン誘導体
|
EP2970288A1
(fr)
|
2013-03-15 |
2016-01-20 |
Vertex Pharmaceuticals Incorporated |
Composés utiles en tant qu'inhibiteurs de la kinase atr
|
WO2014143241A1
(fr)
|
2013-03-15 |
2014-09-18 |
Vertex Pharmaceuticals Incorporated |
Composés utiles en tant qu'inhibiteurs de la kinase atr
|
US9206188B2
(en)
|
2013-04-18 |
2015-12-08 |
Arrien Pharmaceuticals Llc |
Substituted pyrrolo[2,3-b]pyridines as ITK and JAK inhibitors
|
WO2015051302A1
(fr)
|
2013-10-04 |
2015-04-09 |
Aptose Biosciences Inc. |
Compositions et procédés de traitement de cancers
|
UA115388C2
(uk)
|
2013-11-21 |
2017-10-25 |
Пфайзер Інк. |
2,6-заміщені пуринові похідні та їх застосування в лікуванні проліферативних захворювань
|
RU2687276C2
(ru)
|
2013-12-06 |
2019-05-13 |
Вертекс Фармасьютикалз Инкорпорейтед |
Соединения, пригодные для использования в качестве ингибиторов atr киназы
|
WO2015149721A1
(fr)
|
2014-04-04 |
2015-10-08 |
Crown Bioscience, Inc.(Taicang) |
Méthodes permettant de déterminer la sensibilité à des inhibiteurs de mek/erk
|
WO2015155624A1
(fr)
|
2014-04-10 |
2015-10-15 |
Pfizer Inc. |
Dérivés de dihydropyrrolopyrimidine
|
JP6574203B2
(ja)
|
2014-04-30 |
2019-09-11 |
ファイザー・インク |
シクロアルキル結合ジヘテロ環誘導体
|
NZ764151A
(en)
|
2014-06-05 |
2023-12-22 |
Vertex Pharma |
Radiolabelled derivatives of a 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]- pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, the preparation of said compound and different solid forms thereof
|
CA2950780C
(fr)
|
2014-06-17 |
2023-05-16 |
Vertex Pharmaceuticals Incorporated |
Methode de traitement anticancereux utilisant une association d'inhibiteurs de chk1 et d'atr
|
WO2016001789A1
(fr)
|
2014-06-30 |
2016-01-07 |
Pfizer Inc. |
Dérivés de pyrimidine en tant qu'inhibiteurs de pi3k destinés à être utilisés dans le traitement du cancer
|
WO2016011019A1
(fr)
|
2014-07-15 |
2016-01-21 |
The Brigham And Women's Hospital, Inc. |
Compositions et procédés d'inhibition de la bmp
|
US10934360B2
(en)
|
2014-07-31 |
2021-03-02 |
The Hong Kong University Of Science And Technology |
Human monoclonal antibodies against EPHA4 and their use
|
EP3233829B1
(fr)
|
2014-12-18 |
2019-08-14 |
Pfizer Inc |
Dérivés de pyrimidine et de triazine, et leur utilisation comme inhibiteurs d'axl
|
WO2016172214A1
(fr)
|
2015-04-20 |
2016-10-27 |
Tolero Pharmaceuticals, Inc. |
Prédiction de la réaction à l'alvocidib par identification de profil mitochondrial
|
EP3288957A4
(fr)
|
2015-05-01 |
2019-01-23 |
Cocrystal Pharma, Inc. |
Analogues de nucléosides à utiliser pour le traitement d'infections par des virus de la famille des flaviviridae et du cancer
|
KR102608921B1
(ko)
|
2015-05-18 |
2023-12-01 |
스미토모 파마 온콜로지, 인크. |
생체 이용률이 증가된 알보시딥 프로드러그
|
WO2017009751A1
(fr)
|
2015-07-15 |
2017-01-19 |
Pfizer Inc. |
Dérivés de pyrimidine
|
KR20180034538A
(ko)
|
2015-08-03 |
2018-04-04 |
톨레로 파마수티컬스, 인크. |
암의 치료를 위한 병행 요법
|
EP3355926A4
(fr)
|
2015-09-30 |
2019-08-21 |
Vertex Pharmaceuticals Inc. |
Méthode de traitement du cancer utilisant une association d'agents endommageant l'adn et d'inhibiteurs de l'atr
|
EA201891304A1
(ru)
|
2015-12-03 |
2019-01-31 |
Агиос Фармасьютикалс, Инк. |
ИНГИБИТОРЫ MAT2A ДЛЯ ЛЕЧЕНИЯ MTAP-null ЗЛОКАЧЕСТВЕННЫХ ОПУХОЛЕЙ
|
CN106632260B
(zh)
*
|
2016-09-29 |
2019-04-26 |
上海天慈生物谷生物工程有限公司 |
一种小分子激酶抑制剂的制备方法
|
US11279694B2
(en)
|
2016-11-18 |
2022-03-22 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Alvocidib prodrugs and their use as protein kinase inhibitors
|
US10132797B2
(en)
|
2016-12-19 |
2018-11-20 |
Tolero Pharmaceuticals, Inc. |
Profiling peptides and methods for sensitivity profiling
|
US11497756B2
(en)
|
2017-09-12 |
2022-11-15 |
Sumitomo Pharma Oncology, Inc. |
Treatment regimen for cancers that are insensitive to BCL-2 inhibitors using the MCL-1 inhibitor alvocidib
|
WO2019075367A1
(fr)
|
2017-10-13 |
2019-04-18 |
Tolero Pharmaceuticals, Inc. |
Activateurs de pkm2 en combinaison avec des espèces réactives de l'oxygène pour le traitement du cancer
|
CA3103995A1
(fr)
|
2018-07-26 |
2020-01-30 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Procedes de traitement de maladies associees a l'expression anormale d'acvr1 et inhibiteurs d'acvr1 destines a etre utilises dans ceux-ci
|
EP3890749A4
(fr)
|
2018-12-04 |
2022-08-03 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Inhibiteurs de cdk9 et leurs polymorphes destinés à être utilisés en tant qu'agents pour le traitement du cancer
|
WO2020167990A1
(fr)
|
2019-02-12 |
2020-08-20 |
Tolero Pharmaceuticals, Inc. |
Formulations comprenant des inhibiteurs de protéine kinase hétérocycliques
|
JP2022525149A
(ja)
|
2019-03-20 |
2022-05-11 |
スミトモ ダイニッポン ファーマ オンコロジー, インコーポレイテッド |
ベネトクラクスが失敗した急性骨髄性白血病(aml)の処置
|
EP3941463A1
(fr)
|
2019-03-22 |
2022-01-26 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Compositions comprenant des modulateurs de pkm2 et méthodes de traitement les utilisant
|
WO2021155006A1
(fr)
|
2020-01-31 |
2021-08-05 |
Les Laboratoires Servier Sas |
Inhibiteurs de kinases dépendantes des cyclines et leurs utilisations
|
GR1010096B
(el)
*
|
2020-07-02 |
2021-10-08 |
Uni-Pharma Κλεων Τσετης Φαρμακευτικα Εργαστηρια Αβεε, |
Πυραζολο[1,5-a]πυριμιδινες με δραση αναστολης της αυτοταξινης
|